HUTCHMED (China) Limited (HCM)
| Previous Close | 17.38 |
| Open | 18.29 |
| Bid | 18.22 x 100 |
| Ask | 18.36 x 100 |
| Day's Range | 18.29 - 18.57 |
| 52 Week Range | 11.93 - 21.92 |
| Volume | |
| Avg. Volume | 93,215 |
| Market Cap | 3.194B |
| Beta (5Y Monthly) | 0.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.25 |
| Earnings Date | Feb 26, 2025 - Mar 03, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.53 |
GlobeNewswireHUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States, Europe and China — HONG KONG, SHANGHAI & FLORHAM PARK, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a milestone payment following the pricing approval and launch of FRUZA
- GlobeNewswire
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024. Dr Hu has over 20 years of experience in the development of therapeutic antibodies, antibody-drug conjugates, and vaccines. Throughout her caree
- GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds discovered by HUTCHMED will be presented at the American Society of Hematology (“ASH”) Annual Meeting taking place on December 7-10, 2024 in San Diego, USA, and the European Society for Medical Oncology (“
